Key Points
- Director Bethany Sensenig sold 4,475 shares of Supernus Pharmaceuticals (NASDAQ:SUPN) on Feb. 19 at an average price of $51.01, for proceeds of about $228,269.75, according to an SEC filing.
- SUPN opened at $50.69 (12‑month range $29.16–$57.65), has a market cap of $2.91B and a negative P/E (−149.08); analysts are mixed but MarketBeat shows a consensus rating of "Hold" with an average target of $61.60.
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Get Free Report) Director Bethany Sensenig sold 4,475 shares of the stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $51.01, for a total value of $228,269.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Supernus Pharmaceuticals Stock Down 0.3%
Shares of SUPN stock opened at $50.69 on Tuesday. Supernus Pharmaceuticals, Inc. has a twelve month low of $29.16 and a twelve month high of $57.65. The stock's fifty day simple moving average is $50.24 and its 200 day simple moving average is $48.01. The firm has a market capitalization of $2.91 billion, a P/E ratio of -149.08, a P/E/G ratio of 0.64 and a beta of 0.71.
Analyst Ratings Changes
Several research firms have recently issued reports on SUPN. Stifel Nicolaus raised their price objective on shares of Supernus Pharmaceuticals from $50.00 to $55.00 and gave the company a "hold" rating in a report on Friday, December 19th. Bank of America assumed coverage on shares of Supernus Pharmaceuticals in a research report on Wednesday, October 29th. They issued a "buy" rating and a $65.00 price target for the company. Wall Street Zen downgraded shares of Supernus Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Saturday, January 31st. Zacks Research cut shares of Supernus Pharmaceuticals from a "hold" rating to a "strong sell" rating in a research note on Thursday, January 29th. Finally, Weiss Ratings restated a "sell (d+)" rating on shares of Supernus Pharmaceuticals in a report on Monday, December 29th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $61.60.
Get Our Latest Stock Analysis on SUPN
Institutional Inflows and Outflows
Several hedge funds have recently made changes to their positions in the business. Smartleaf Asset Management LLC boosted its position in shares of Supernus Pharmaceuticals by 30.8% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,137 shares of the specialty pharmaceutical company's stock valued at $54,000 after purchasing an additional 268 shares in the last quarter. Arizona State Retirement System lifted its stake in Supernus Pharmaceuticals by 1.7% in the third quarter. Arizona State Retirement System now owns 16,547 shares of the specialty pharmaceutical company's stock valued at $791,000 after buying an additional 277 shares during the period. Hantz Financial Services Inc. lifted its stake in Supernus Pharmaceuticals by 81.7% in the third quarter. Hantz Financial Services Inc. now owns 625 shares of the specialty pharmaceutical company's stock valued at $30,000 after buying an additional 281 shares during the period. Maryland State Retirement & Pension System boosted its holdings in shares of Supernus Pharmaceuticals by 3.6% during the 4th quarter. Maryland State Retirement & Pension System now owns 8,351 shares of the specialty pharmaceutical company's stock worth $415,000 after buying an additional 290 shares in the last quarter. Finally, SummitTX Capital L.P. grew its position in shares of Supernus Pharmaceuticals by 2.7% during the 4th quarter. SummitTX Capital L.P. now owns 11,670 shares of the specialty pharmaceutical company's stock worth $580,000 after buying an additional 303 shares during the period.
Supernus Pharmaceuticals Company Profile
(
Get Free Report)
Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.
The company's marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
